256 related articles for article (PubMed ID: 23336938)
1. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
[TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
3. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Almeida AM; Pierdomenico F
Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
[No Abstract] [Full Text] [Related]
4. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
5. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
6. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R; Thépot S; Beyne-Rauzy O; Ame S; Isnard F; Dreyfus F; Salanoubat C; Taksin AL; Chelgoum Y; Berthon C; Malfuson JV; Legros L; Vey N; Turlure P; Gardin C; Boehrer S; Ades L; Fenaux P;
Leuk Res; 2012 Apr; 36(4):397-400. PubMed ID: 22177456
[TBL] [Abstract][Full Text] [Related]
7. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
9. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
10. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
12. Decitabine dosage in myelodysplastic syndromes.
Giagounidis AA
Blood; 2007 Aug; 110(3):1082-3; author reply 1083. PubMed ID: 17644750
[No Abstract] [Full Text] [Related]
13. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Durairaj S; Keenan N; Hyslop A; Groves MJ; Bowen DT; Tauro S
Br J Haematol; 2013 Apr; 161(2):280-2. PubMed ID: 23294041
[No Abstract] [Full Text] [Related]
14. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
15. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
16. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
17. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
Duong VH; Lin K; Reljic T; Kumar A; Al Ali NH; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):711-5. PubMed ID: 24054159
[TBL] [Abstract][Full Text] [Related]
18. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
Iastrebner M; Jang JH; Nucifora E; Kim K; Sackmann F; Kim DH; Orlando S; Jung CW; Basquiera A; Klein G; Santini F; Bernard HI; Korin J; Taborda G
Leuk Lymphoma; 2010 Dec; 51(12):2250-7. PubMed ID: 20929328
[TBL] [Abstract][Full Text] [Related]
19. Concise drug review: azacitidine and decitabine.
Derissen EJ; Beijnen JH; Schellens JH
Oncologist; 2013; 18(5):619-24. PubMed ID: 23671007
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
